Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Tesamorelin and Sermorelin are two synthetic peptides that belong to the growth-hormone-releasing hormone (GHRH) analog family. Both are studied for their interaction with the GHRH receptor (GHRHR) expressed on somatotroph cells of the anterior pituitary, the same molecular target engaged by endogenous hypothalamic GHRH. In laboratory and preclinical research models, this receptor interaction is examined for its capacity to stimulate the pulsatile secretion of endogenous growth hormone (GH) and the downstream signaling that follows along the GH/IGF-1 axis.
Although the two peptides share a receptor and a mechanistic starting point, they differ substantially in sequence length, molecular weight, N-terminal chemistry, and reported metabolic stability. This comparison contrasts Tesamorelin and Sermorelin strictly as research compounds, outlining what distinguishes them at the structural level and how those differences frame the questions investigators ask about each. All material here is for research use only, not for human consumption.
Shared Target: The GHRH Receptor Pathway
Growth-hormone-releasing hormone is a hypothalamic peptide that travels through the hypophyseal portal circulation to the anterior pituitary, where it binds the GHRH receptor, a class B G-protein-coupled receptor. Receptor engagement raises intracellular cyclic AMP within somatotroph cells and promotes the synthesis and pulsatile release of growth hormone. Both Tesamorelin and Sermorelin are designed to engage this same receptor, which is why they are grouped together as GHRH analogs rather than as direct growth hormone substitutes.
How GHRH signaling is studied
In cell-based and animal research, GHRH analogs serve as tools to probe somatotroph responsiveness, receptor density, and the feedback relationships that connect growth hormone to insulin-like growth factor 1 (IGF-1). Because these peptides act upstream, on the pituitary itself, they are often contrasted with secretagogues that work through the separate ghrelin (GH secretagogue) receptor. The distinction matters for experimental design, because GHRH analogs and ghrelin-mimetic peptides converge on growth hormone output through different receptors.
Why analog design matters
Native GHRH is short-lived in circulation because enzymes such as dipeptidyl peptidase-4 (DPP-4) cleave it rapidly near its N-terminus. A central theme in GHRH-analog chemistry is protecting that vulnerable region. The two peptides compared here represent two different answers to that problem: one preserves only the minimal active fragment, while the other adds a chemical cap intended to slow degradation. This is the structural fork that separates Sermorelin from Tesamorelin.
Structural Profiles of Each Peptide
Sermorelin: GHRH(1-29)
Sermorelin corresponds to the first 29 residues of human GHRH, the shortest N-terminal fragment that retains the receptor-activating capacity of the full-length hormone in research models. With a chain length of 29 amino acids and an approximate molecular weight of 3358 g/mol, it is the more compact of the two molecules. Its N-terminus is unmodified, so under laboratory conditions it is generally reported to have a short circulating half-life, a property that makes it useful for studying rapid, transient somatotroph stimulation.
Tesamorelin: a stabilized GHRH(1-44) analog
Tesamorelin is built on the complete GHRH(1-44) sequence and carries a trans-3-hexenoic acid (hexenoyl) group attached to its N-terminus. That added acyl cap is its defining structural feature, because it is intended to shield the peptide from N-terminal enzymatic cleavage, a modification associated in the literature with greater metabolic stability relative to the unmodified fragment. At roughly 44 amino acids plus the hexenoyl modification, and an approximate molecular weight of 5136 g/mol, Tesamorelin is the larger and structurally more elaborate peptide of the pair. It has been a frequent subject of research into the GH/IGF-1 axis and metabolic pathways involving visceral adipose tissue. The Tesamorelin research peptide and Sermorelin research peptide are each supplied in lyophilized form for laboratory use.
Tesamorelin vs Sermorelin: Side-by-Side Comparison
The following values reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Tesamorelin | Sermorelin |
|---|---|---|
| Compound class | Stabilized GHRH(1-44) analog | GHRH(1-29) N-terminal fragment |
| Sequence length | 44 amino acids plus hexenoyl cap | 29 amino acids |
| Approximate molecular weight | ~5136 g/mol | ~3358 g/mol |
| Molecular formula | C221H366N72O67S | C149H246N44O42S |
| N-terminal modification | trans-3-hexenoic acid (hexenoyl) | None (native N-terminus) |
| Receptor target | GHRH receptor (GHRHR) | GHRH receptor (GHRHR) |
| Reported metabolic stability | Higher (N-terminal cap resists cleavage) | Lower (short reported half-life) |
| Physical form | Lyophilized powder | Lyophilized powder |
Read together, the table shows that the two peptides diverge less in their target than in their construction. They share an identical receptor while differing in molecular size, N-terminal chemistry, and reported stability. For researchers, that means the choice between them is usually framed around how long a stimulus is meant to persist in a given model rather than which receptor is engaged.
Research Handling and Related GH-Axis Peptides
Both peptides are typically supplied as lyophilized powders and reconstituted with bacteriostatic water for laboratory handling. As a worked example, adding 2 mL of bacteriostatic water to a 5 mg vial yields a concentration of 2.5 mg/mL, while the same 2 mL added to a 10 mg vial yields 5 mg/mL. Detailed technique, including swirling rather than shaking and minimizing freeze-thaw cycles, is covered in the bacteriostatic water reconstitution guide. Reconstituted material is generally kept refrigerated and protected from prolonged light exposure.
Verifying identity and purity is a routine part of comparative work. A certificate of analysis reports mass-spectrometry identity and chromatographic purity, letting researchers confirm that a Tesamorelin or Sermorelin lot matches its stated molecular weight before an experiment begins. Investigators comparing GHRH analogs frequently extend the comparison to co-studied secretagogues such as CJC-1295, another GHRH-analog peptide, and browse the broader research peptide catalog to source matched material. Every item is offered strictly for research use only, not for human consumption.
Frequently Asked Questions
What is the difference between tesamorelin and sermorelin?
Both are GHRH analogs that act on the same pituitary GHRH receptor, but they differ in structure. Sermorelin is the 29-amino-acid N-terminal fragment of GHRH, while Tesamorelin is a 44-amino-acid GHRH analog carrying an N-terminal trans-3-hexenoic acid group that is associated with greater metabolic stability in the research literature.
Are tesamorelin and sermorelin both GHRH analogs?
Yes. Each peptide is derived from growth-hormone-releasing hormone and engages the GHRH receptor on anterior pituitary somatotrophs. They are studied as upstream stimulators of endogenous growth hormone rather than as growth hormone itself.
How do the molecular weights of tesamorelin and sermorelin compare?
Tesamorelin is the heavier molecule at approximately 5136 g/mol, reflecting its longer 44-residue chain and hexenoyl modification. Sermorelin is smaller at approximately 3358 g/mol across its 29-residue sequence. These values are commonly reported laboratory attributes and are provided for comparison only.
Which has a longer reported half-life, tesamorelin or sermorelin?
Sermorelin, with its unmodified N-terminus, is generally reported to clear quickly in laboratory studies, whereas the N-terminal cap on Tesamorelin is intended to slow enzymatic cleavage and is associated with longer reported stability. Exact figures vary with study conditions.
How are tesamorelin and sermorelin stored and reconstituted in research settings?
Both are typically supplied as lyophilized powder, reconstituted with bacteriostatic water, and kept refrigerated with limited light exposure and minimal freeze-thaw cycling. Consult the linked bacteriostatic water guide for detailed handling technique.
Are tesamorelin and sermorelin approved for human use?
No. Within this catalog, both compounds are offered strictly as research materials for laboratory and educational purposes. They are not intended for human consumption, self-administration, or therapeutic use.
References and Further Reading
- Guillemin R, et al. (1982). Isolation and characterization of growth-hormone-releasing factor. PubMed: growth hormone releasing factor Guillemin 1982
- GHRH receptor signaling in pituitary somatotrophs. PubMed: GHRH receptor somatotroph signaling
- Sermorelin (GRF 1-29) structure and pharmacology. PubMed: sermorelin GRF 1-29
- Tesamorelin as a stabilized GHRH analog. PubMed: tesamorelin GHRH analog
- Tesamorelin research on the GH/IGF-1 axis and visceral adipose tissue. PubMed: tesamorelin visceral adipose tissue
- Dipeptidyl peptidase-4 and N-terminal degradation of GHRH peptides. PubMed: GHRH dipeptidyl peptidase degradation
- Growth hormone and IGF-1 axis regulation. PubMed: growth hormone IGF-1 axis
